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Background: KLF8 is a cancer-promoting transcription factor.
Results: KLF8 inhibits DNA damage in breast cancer cells.
Conclusion: KLF8 is a novel effector of the PARP-1 and DNA-PK DNA damage response pathways.
Significance: KLF8 could be targeted for chemosensitizing therapy.

In actively dividing normal cells, the genomic integrity is
constantly threatened by DNA damage, resulting in DNA
lesions such as single-strand breaks (SSBs)2 and double-strand
breaks (DSBs) (1). To maintain the genomic integrity and thus
avoid cell death or transformation, normal cells have inherited
a variety of DNA repair mechanisms that fix SSBs or DSBs by
the master sensors and regulators of DNA damage such as poly(ADP-ribose) polymerase 1 (PARP-1), BRCA1, BRCA2, and
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DNA-dependent protein kinase (DNA-PK) (2–5). In addition,
many types of posttranslational modifications of proteins, such
as SUMOylation, have been shown to play a critical role in the
DNA repair processes (6, 7).
Because of their genotoxic and, thus, cytotoxic effect on cancer cells, DNA-damaging agents have been the mainstay of cancer therapy for decades. However, DNA damage responses by
suboptimal or inaccurate DNA repair mechanisms not only
arm cancer cells with therapeutic resistance but also contribute
to aggressive progression of tumors by causing genomic instability (1). For this reason, inhibitors targeting DNA repair proteins such as PARP-1 and DNA-PK have been actively developed and tested to improve the cancer therapy (1).
Understanding how cancer cells improperly respond to DNA
damage is critical for designing novel anti-DNA repair therapeutic strategies for cancer.
Krüppel-like transcription factor 8 (KLF8) is aberrantly overexpressed in a variety of human cancers and promotes transformation or tumor progression of these cancers, including breast
cancer (8 –10), ovarian cancer (9, 11), hepatocellular carcinoma
(12), renal cancer (11, 13), gastric cancer (14), and glioma (15–
17). Interestingly, the nuclear function of KLF8 is tightly regulated by its posttranslational modifications, including SUMOylation (18, 19) and PARP-1-catalyzed PARylation (20, 21) to
regulate the transcription of genes such as cyclin D1 (10, 18, 19,
22, 23), E-cadherin (10, 12), and MMP9 (8) that are essential for
tumor progression.
In this work, we report the discovery of a novel role of KLF8
in promoting DNA repair and drug resistance in breast cancer
cells and the underlying molecular mechanisms involving
interaction with PARP-1, the DNA-PK catalytic subunit (DNAPKcs), and PIASs and their catalyzed PARylation, phosphorylation, and sumoylation. Our results suggest that KLF8 could
be a critical factor contributing to therapeutic resistance in
breast cancer through improper DNA damage response.

1
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EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Antibodies against the HA tag
(F-7), Myc tag (9E10), PARP-1, H2A.X (sc-54607), and DNAPKcs (sc-5282) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-␥-H2A.X (9718S) antibody was
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Krüppel-like factor 8 (KLF8) regulates critical gene transcription and cellular events associated with cancer. However, the
role of KLF8 in cancer remains largely unknown. Here, we
report a surprisingly novel role for KLF8 in DNA repair in breast
cancer cells. Comet, clonogenic, and WST-1 assays showed that
KLF8 expression is required for protecting human breast cancer
cells from doxorubicin-induced DNA damage and cell death.
Western blotting indicated that overexpression of ectopic KLF8
attenuated the levels of the DNA damage marker ␥H2A.X in
doxorubicin-treated PARP-1ⴙ/ⴙ but not PARP-1ⴚ/ⴚ mouse
embryonic fibroblasts, whereas the PARP-1-binding-defective
KLF8 mutant failed to do so. Interestingly, in response to the
DNA damage, KLF8 was phosphorylated by the DNA-dependent protein kinase catalytic subunit and, subsequently,
SUMOylated by SUMO E3 ligases protein inhibitors of activated
STAT (PIASs), which depends upon the interaction of KLF8
with DNA-dependent protein kinase catalytic subunit, PIASs,
and PARP-1 as well as their enzymatic activities. Lastly, we show
evidence that KLF8 was recruited to the DNA damage site.
These results suggest a novel role and mechanism for KLF8 in
the regulation of DNA repair and therapeutic resistance in
breast cancer cells.

KLF8 Regulates DNA Repair
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Clonogenic Assay—Cell survival rates after doxorubicin
treatment were performed as described (30). Briefly, the 10AiK8 cells or 231-K8ikd cells were grown under induced or uninduced conditions for 2 days. MCF-10A cells were transfected
with wild-type or mutant KLF8 for 24 h. The cells were then
treated with doxorubicin, reseeded at low density, and allowed
to grow for 2 weeks to allow colonies to form. Colonies were
fixed with 3.7% paraformaldehyde, stained with 0.1% crystal
violet, and counted. Colonies containing ⬃50 or more cells
were counted.
WST-1 Assay—The cell sensitivity to the cytotoxic effect of
doxorubicin was assayed using Clontech WST-1 cell proliferation reagent (catalog no. 630118) according to the instructions
of the manufacturer (PT3946-1) (Clontech Laboratories, Inc.,
Mountain View, CA). Briefly, cells of appropriate density were
seeded and treated similarly as in a clonogenic assay. After
being grown for 48 h, the cells were incubated with the WST-1
reagent for 2 h before optical density (A) values at 440-nm
wavelength were measured using a multiplate bioreader
(PerkinElmer Life Sciences). The OD values represent the cell
viability.
DNA Damage Induction, ␥H2A.X Detection, and Comet
Assay—Cellular DNA damage was induced by treating the cells
in culture with the DNA-intercalating agent doxorubicin.
Overall DNA damage levels were assessed by Comet assay using
alkaline single-cell agarose gel electrophoresis and the Trevigen
Comet assay kit (4250-050-K, Gaithersburg, MD) according to
the instructions of the manufacturer. Briefly, cells were treated
with doxorubicin with certain doses or at certain time points,
harvested, and subjected to Comet analysis. After staining with
SYBR Green, Comet images were captured by fluorescence
microscopy. Tail moments (percentage of DNA in tail ⫻ tail
length) were quantitated for 100 cells/slide using CometScore
software. Western blotting was performed to determine the
levels of ␥H2A.X, a marker for double-strand breaks of damaged DNA. Western blot analyses were quantified by chemiluminescence blot of Image Lab 3.0 (Bio-Rad). To control the
exposure time between blots, for every panel, all membranes
were exposed for the same duration. Then the quantitative data
from three independent experiments were statistically analyzed. The reduction in the levels of DNA damage during the
period of cell recovery post-doxorubicin removal was considered an indicator for DNA repair.
Statistical Analysis—All the data were summarized and presented as mean ⫾ S.D. with a minimum of three observations
per group. Unpaired, paired or single sample Student’s t test
with the Bonferroni correction for the multiple comparisons or
Qi-Square test was applied as appropriate. Significance was
determined by the ␣ level of 0.05.

RESULTS
The Aberrantly Overexpressed KLF8 Protects Breast Cancer
Cells from Doxorubicin-induced Cell Death by Reducing the
Levels of DNA Damage—To test whether KLF8 expression protects breast cancer cells from death induced by DNA-damaging
agent, we first treated our 231-K8ikd cells (an MDA-MB-231
variant expressing aberrantly high levels of endogenous KLF8
and Tet-on inducible short hairpin RNA against KLF8 (26))
JOURNAL OF BIOLOGICAL CHEMISTRY
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purchased from Cell Signaling Technology, Inc. (Danvers,
MA). Anti-phosphoserine was purchased from Chemicon
(EMD Millipore Corp., Billerica, MA). Anti-HA and anti-Myc
antibody-conjugated agarose beads and PJ-34 were purchased
from Sigma. IgG was purchased from Jackson ImmunoResearch, Inc. (West Grove, PA). Doxorubicin (324380) was
purchased from Calbiochem (EMD Millipore Corp.). Olaparib
and ABT-888 (ABT) were purchased from Selleck Chemical
LLC (Houston, TX). Nu7026 was purchased from Cayman
Chemical Co. (Ann Arbor, MI).
Cell Culture, Transfection, and Plasmid Construction—
HEK293T was purchased from the ATCC. The PARP-1⫹/⫹ and
PARP-1⫺/⫺ primary mouse embryonic fibroblast (MEF) cells
(20, 24, 25), the MCF-10A line that expresses inducible KLF8
(10A-iK8), and the MDA-MB-231 line that expresses inducible
KLF8 short hairpin RNA (231-K8ikd) (26) were described previously. Transfections of the plasmid DNAs were performed
using Lipofectamine 2000 (Invitrogen) according to the
instructions of the manufacturer. The mammalian expression
plasmids pKH3, pKH3-KLF8, pHAN-PARP-1, -PIAS1, -PIAS2,
-PIAS4, -SUMO-1, and the ZF1,2mCs and K67R mutants of
KLF8 were described previously (18, 20 –22). The pKH3KLF8S80A serine-to-alanine mutant was generated by site-directed mutagenesis PCR and overlapping PCR using pKH3KLF8 as the template and the mutation-specific primers of
5⬘-tag tga ttt cgc cct gcc c-3⬘ (forward) and 5⬘-tgg ggc agg gcg
aaa tca c-3⬘ (reverse) paired with one of the master primers of
5⬘-CCC AAG CTT CTG CAG GTC G-3⬘ (forward) and
5⬘-GGA CAA ACC ACA ACT AGA ATG CAG-3⬘ (reverse).
RNA Interference, Quantitative Real-time PCR, Western Blotting, Coimmunoprecipitation (Co-IP), and SUMOylation
Assays—These assays were performed as described previously
(10, 18, 19, 23). PARP-1 and GFP ON-TARGETplus siRNAs
were purchased from Dharmacon (J006656-05, 5⬘-GAU UUC
AUC UGG UGU GAU A-3⬘; J006656-06, 5⬘-GAA AAC AGG
UAU UGG AUA U-3⬘; J006656-07, 5⬘-GUU CUU AGC GCA
CAU CUU G-3⬘; and J006656-08, 5⬘-CCA AUA GGC UUA
AUC CUG U-3⬘). DNA-PKcs siRNAs (sc-35200) were purchased from Santa Cruz Biotechnology, Inc. Oligofectamine
was used to transfect siRNAs according to the instructions of
the manufacturer (Invitrogen). Primers for quantitative realtime PCR (forward/reverse) are as follows: GAPDH, 5⬘-tcg tac
gtg gaa gga ctc a-3⬘ (forward) and 5⬘-cca gta gag gca ggg atg
at-3⬘(reverse) and H2A.X, 5⬘-aga tcc tgg agc tgg c-3⬘ (forward)
and 5⬘-acg gcc tgg atg ttg g-3⬘ (reverse).
ChIP Assays—The cyclin D1 gene promoter reporter assays
were performed as described previously (23, 27). DNA damage
site-targeted ChIP assays were carried out (28) to determine the
recruitment of KLF8 to the DNA damage sites. Briefly, the DNA
DSB reporter pDR-GFP that contains an I-SceI endonuclease
recognition site was stably transfected into the 10A-iK8 cells.
The established 10A-iK8/DR-GFP cells were treated with 1 M
tetracycline for 24 h for the induction of KLF8 expression.
Then, the site-specific DNA DSB was induced by transfection
of the I-SceI expression plasmid pC␤ASce. After 24 h, the ChIP
assays were performed using the DNA damage site-specific
PCR primer set DR-1 (adjacent to the DNA DSBs) (29).

KLF8 Regulates DNA Repair

with the DNA-damaging drug doxorubicin and examined the
correlation between cell survival and KLF8 expression levels in
the cells using clonogenic assays (Fig. 1, A and C, left panels).
We found that when KLF8 knockdown was induced (I), the cells
became more sensitive to doxorubicin-induced cell death than
when KLF8 knockdown was uninduced (U). Conversely, in our
10A-iK8 cells (a MCF-10A cell line expressing little or no
endogenous KLF8 and Tet-on inducible ectopic KLF8 (26)), the
cells became more resistant to doxorubicin-induced death
when the ectopic KLF8 expression was induced (I) than when
the ectopic KLF8 expression was uninduced (U) (Fig. 1, A and
C, right panels). Similar results were reproduced by the independent cell viability analysis using WST-1 assays (Fig. 1, B and
D).
To test whether the expression levels of KLF8 in the cells
affect the levels of DNA damage induced by doxorubicin, the
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cells were treated with doxorubicin similarly, and the levels of
DNA damage were determined by Comet assays. The results
showed that in both the 231-K8ikd and 10A-iK8 cells, the levels
of KLF8 expression and the levels of doxorubicin-induced DNA
damage were inversely correlated (Fig. 1, E and F). These results
were further verified by an independent analysis of the induction of phosphorylated form of histone 2A.X, i.e. ␥-H2A.X, a
marker for DNA DSBs, using Western blotting (Fig. 1G).
These data clearly indicate that the aberrant overexpression
of KLF8 in breast cancer cells is critical for the prevention of
DNA damage, promotion of DNA repair, or both, and the subsequent resistance to the DNA damage-induced cell death.
KLF8 Attenuates DNA Damage in a PARP-1-dependent
Manner—We have recently identified the KLF8 interaction
with and regulation by PARP-1, a master regulator of DNA
repair (1, 20). To determine whether PARP-1 plays a role in
VOLUME 287 • NUMBER 52 • DECEMBER 21, 2012
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FIGURE 1. KLF8 protects breast epithelial and cancer cells from doxorubicin-induced cell death by reducing DNA damage levels. A–D, overexpression
of KLF8 confers resistance to doxorubicin-induced cell death. Cells were pretreated with 1 M tetracycline for 48 h to induce KLF8 knockdown in the 231-K8ikd
cells or overexpression in 10A-ik8 cells. After 4 h of treatment at the indicated doses (A and B) or 1 M treatment for indicated periods of time (C and D) with
doxorubicin and 2 h of recovery, the cells were prepared for clonogenic assay (A and C) or WST-1 assay (B and D). E and F, KLF8 promotes repair of doxorubicininduced DNA damage. Cells were treated as in A. DNA damage levels were assessed using a Comet assay after the 4-h induction of DNA damage by doxorubicin
of various doses, followed by 2 h of recovery (E) or after various time periods of DNA damage induction by 1 M doxorubicin (F). G, KLF8 attenuates the levels
of DSBs induced by doxorubicin. The cells were treated as in A. Whole cell lysates were collected as in E (top) or F (bottom) for assessing the expression of the
DSB marker ␥-H2A.X by Western blotting. The data represent the mean ⫾ S.E. of at least three independent triplicate experiments. *, p ⬍ 0.05. I, induced; U,
uninduced.

KLF8 Regulates DNA Repair

KLF8-induced reduction in DNA damage caused by doxorubicin, we first transfected the PARP-1⫹/⫹ primary MEF cells (20,
24, 25) with either the wild-type KLF8 or its PARP-1 bindingdefective mutant ZF1,2mCs and compared the sensitivity
between the wild-type and mutant KLF8-transfected cells to
doxorubicin-induced DNA damage. We found that the cells
transfected with the wild-type KLF8 showed a much lower level
of ␥H2A.X than that shown in the vector-transfected cells (Fig.
2A, compare lanes or columns 4 and 2), consistent with the
observations in the breast cells described above in Fig. 1. In
contrast, the cells transfected with the mutant KLF8 maintained a level of ␥H2A.X that was comparable with that in the
vector-transfected control cells and much higher than that in
the wild-type KLF8-transfected cells (Fig. 2A, compare lane or
column 6 to lanes 2 or 4). These results indicate that the interDECEMBER 21, 2012 • VOLUME 287 • NUMBER 52
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FIGURE 2. KLF8 attenuates DNA damage-induced phosphorylation of
H2A.X in a PARP-1-dependent manner. A, KLF8-mediated decrease in
␥H2A.X levels upon DNA damage requires its interaction with PARP-1. PARP1⫹/⫹ cells were transfected with HA-KLF8, HA-ZF1,2mCs (the PARP-1 interaction-defective mutant of KLF8 (20)), or vector alone for 24 h. DNA damage was
induced by doxorubicin (Doxo) (1 M) treatment for 4 h. Whole cell lysates
were prepared for Western blotting of ␥H2A.X. Left panel, representative
image of Western blot analysis. Right panel, quantitative analysis of related
␥H2A.X levels. B, KLF8-mediated reduction of ␥H2A.X requires catalytically
active PARP-1. PARP-1⫺/⫺ cells were transfected with HA-KLF8, PARP-1,
E988K (the auto-PARylation-defective mutant of PARP-1 (20)), or vector alone
for 24 h and treated with doxorubicin (1 M) for 4 h. Whole cell lysates were
prepared for Western blotting (left panel) and quantitative analysis (right
panel) of related ␥H2A.X levels. C, KLF8 does not impact H2A.X expression at
mRNA levels. PARP-1⫹/⫹ cells were transfected with HA-KLF8 or vector alone
for 24 h. Total RNA was prepared and used for examination of H2A.X mRNA
expression levels by RT-PCR (left panels) and qRT-PCR (right panel). Data represent the mean ⫾ S.E. of at least three independent duplicate experiments. *,
p ⬍ 0.05.

action of KLF8 and PARP-1 is critical for the KLF8-induced
decrease in the levels of DNA damage in the cells.
To test whether the catalytic activity of PARP-1 is also
involved, we transfected the PARP-1⫺/⫺ MEFs with the wildtype PARP-1 or its auto-PARylation-defective mutant E988K
(20, 25) along with KLF8 for 24 h, treated the cells with doxorubicin (1 M) for 4 h, and then determined the difference in the
levels of DNA damage between the wild-type and mutant
PARP-1-transfected cells by Western blotting of ␥H2A.X. The
result showed that without PARP-1 re-expression in the cells,
overexpression of KLF8 did not cause a reduction in the levels
of DNA damage (Fig. 2B, compare lanes or columns 4 and 2).
Coexpression of wild-type PARP-1 restored the KLF8-induced
reduction in the DNA damage levels, but the mutant PARP-1
failed to do so (Fig. 2A, compare lanes or columns 5 or 6 to 2 or
4), indicating that PARP-1-catalyzed auto-PARylation or transPARylation also plays an important role in KLF8 regulation of
the DNA damage response.
These results suggest that it is important for KLF8 to interact
with catalytically active PARP-1 to antagonize DNA damage.
The results also suggest that KLF8 reduces the levels of DNA
damage primarily by promoting DNA repair rather than preventing DNA damage in the cells, given that PARP-1 plays a
critical role in DNA repair and that KLF8 does not appear to
have an impact on the expression of H2A.X (Fig. 2C).
SUMOylation of KLF8 Is Induced by DNA Damage and This
Modification is PARP-1-dependent and Essential for KLF8-mediated DNA Repair and Protection against Cell Death—It has
been reported that KLF8 is regulated by SUMOylation (18, 19,
31), and SUMOylation plays an important role in DNA repair
(6). To test whether doxorubicin treatment causes any change
in the SUMOylation of KLF8 and possible involvement of
PARP-1, we cotransfected the PARP-1⫹/⫹ and PARP-1⫺/⫺
MEFs with wild-type KLF8 or its ZF1,2mCs mutant and
SUMO-1 and examined the SUMOylation state of the KLF8
proteins. We found that in the presence of PARP-1, the
SUMOylation of the wild-type KLF8 was highly stimulated by
doxorubicin treatment (Fig. 3A, compare lane 3 to lane 1), and
the SUMOylation remained at a high level within 2 h after
doxorubicin was removed (Fig. 3A, compare lane 5 to lane 1,
and B). In contrast, in the absence of PARP-1, doxorubicin failed
to stimulate the SUMOylation of the wild-type KLF8 (Fig. 3A,
compare lane 9 to lane 7). Little or no SUMOylation of the
ZF1,2mCs mutant took place regardless of the expression of
PARP-1 (Fig. 3A, compare lane 4 to lane 2 or lane 10 to lane 8).
These results clearly indicate that KLF8 responds to doxorubicininduced DNA damage through the SUMOylation of it and that the
SUMOylation depends upon its interaction with PARP-1.
To test whether the SUMOylation of KLF8 plays a role in
DNA repair, we transfected the PARP-1⫹/⫹ MEFs with the
wild-type KLF8 or its K67R SUMOylation-defective mutant
(18) and compared their effect on the expression levels of
␥H2A.X. As expected, the wild-type KLF8 reduced ␥H2A.X
back to the basal level (Fig. 3C, compare lanes 3 or 4 to lane 1 or
columns 5 or 6 to 4). The K67R mutant, however, failed to do so
(Fig. 3C, compare lanes 6 or 7 to lane 1 or columns 8 or 9 to
column 7). These results suggest that the SUMOylation of KLF8
is critical for the DNA repair.

KLF8 Regulates DNA Repair

We then transfected the PARP-1⫹/⫹ or PARP-1⫺/⫺ MEFs
with the wild-type KLF8 and the ZF1,2mCs or K67R mutant
and determined their role in protecting the cells from doxorubicin-induced cell death. We found that the wild-type KLF8
enhanced the viability of the PARP-1⫹/⫹ but not the PARP1⫺/⫺ cells (Fig. 3D, compare column 3 to column 2 or column 8
to column 7), whereas both of the KLF8 mutants failed to do the
same (Fig. 3D, compare lanes 4 or 5 to lanes 2 or 3). Taken
together, these results suggest that the PARP-1-dependent
SUMOylation of KLF8 is critical for DNA repair and resistance
to DNA-damage-mediated cell death.
The DNA Damage-induced SUMOylation of KLF8 Is Mediated via Interaction between KLF8, PIASs, and Catalytic
PARP-1—To determine the molecular mechanisms by which
the SUMOylation of KLF8 is induced during doxorubicin-in-
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duced DNA damage, we first examined the role of PARP-1 for
KLF8 interaction with the SUMO E3 ligases PIASs. Coexpression and co-IP analyses demonstrated that, unlike the wild-type
KLF8 and the K67R mutant, the HA-ZF1,2mCs mutant hardly
interacted with the PIASs (Fig. 4A, lanes 2, 5, and 8). On the
other hand, the wild-type KLF8 barely interacted with PIASs
either in the absence of PARP-1 (Fig. 4B). Treatment with
doxorubicin dramatically enhanced the interaction between
KLF8 and PIASs in the presence of PARP-1 (Fig. 4B). These
results suggest that KLF8 interaction with PARP-1 is critical
for the interaction between KLF8 and PIASs and subsequent
sumoylation of KLF8 by PIASs during DNA damage
response.
To test whether the PARylation activity of PARP-1 is
involved in the SUMOylation of KLF8, we cotransfected the
VOLUME 287 • NUMBER 52 • DECEMBER 21, 2012
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FIGURE 3. KLF8 responds to DNA damage through PARP-1-dependent SUMOylation. A, SUMOylation of KLF8 is stimulated by DNA damage, requiring its
interaction with PARP-1. PARP-1⫹/⫹ or PARP-1⫺/⫺ MEFs were cotransfected with HA-KLF8 or HA-ZF1,2mCs with Myc-SUMO-1 for 24 h, treated with 1 M
doxorubicin for 4 h, and followed by 2 h of recovery. Whole cell lysates were prepared at the end of mock treatment (lanes 1, 2, 7, and 8), doxorubicin
treatment (lanes 3, 4, 9, and 10) or recovery (lanes 5, 6, 11, and 12) for Western blotting (IB) and co-IP (IP). B, dynamic changes of SUMOylation on KLF8
during recovery from DNA damage. 293T cells were cotransfected with HA-KLF8 and Myc-SUMO-1 at a ratio of 5:1 for 24 h and then treated with 1 M
doxorubicin for 4 h. Whole cell lysates were prepared at indicated times post-doxorubicin removal for Western blotting and co-IP. C, the SUMOylation
of KLF8 is required for the DNA repair. PARP-1⫹/⫹ cells were transfected with HA-KLF8, HA-K67R (the SUMOylation-defective mutant of KLF8 (18)), or
vector alone for 24 h, treated with indicated concentrations of doxorubicin (Doxo) for 4 h, and followed by 2 h of recovery. Whole cell lysates were
prepared for Western blotting and quantification of ␥H2A.X levels. D, SUMOylation of KLF8 and its interaction with PARP-1 are both essential for cell
viability post-DNA damage. PARP-1⫹/⫹ and PARP-1⫺/⫺ MEFs were transfected with HA-KLF8, HA-ZF1,2mCs, HA-K67R, or vector alone for 24 h, treated
for 4 h with 1 M doxorubicin, and collected for WST-1 assay. Data represent the mean ⫾ S.E. of at least three independent duplicate experiments. *, p ⬍
0.05. The arrows indicate the major band of SUMOylated KLF8 protein.
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FIGURE 4. SUMOylation of KLF8 is mediated by its interaction with PIASs
and catalytic active PARP-1. A, the PARP-1 binding-defective mutant of
KLF8 fails to interact with PIASs. 293T cells were cotransfected with HA-KLF8,
HA-ZF1,2mCs, or HA-K67R with Myc-PIAS-1, -2, or -4 for 24 h. Whole cell
lysates were prepared for Western blotting (IB) and co-IP (IP). B, KLF8 interaction with PIASs depends on PARP-1 expression and is enhanced by DNA damage. PARP-1⫹/⫹ MEFs and PARP-1⫺/⫺ MEFs were cotransfected with HA-KLF8
and Myc-PIAS-1, -2, or -4, for 24 h. Whole cell lysates were prepared for Western blotting and co-IP. C, DNA damage-induced SUMOylation of KLF8
requires catalytically active PARP-1. PARP-1⫹/⫹ MEFs were cotransfected with
HA-KLF8 and Myc-SUMO-1 for 24 h and treated first with the PARP-1 inhibitor
PJ-34 for 24 h and then with doxorubicin (Doxo) for another 4 h. Whole cell
lysates were prepared for Western blotting and co-IP. HA-K67R was used as a
SUMOylation-negative control. The arrowheads indicate SUMOylated KLF8.
D, recovery from the DNA damage releases PARP-1 and KLF8 from PIAS1.
PARP-1⫹/⫹ cells were cotransfected with Myc-PIAS1 and HA-KLF8 for 24 h and
treated with doxorubicin for 4 h. Whole cell lysates were collected at indicated time points after doxorubicin was removed for Western blotting and
co-IP. E, the catalytic activity is required for PARP-1 interaction with PIAS1.
PARP-1⫹/⫹ cells were transfected with Myc-PIAS1 for 24 h and treated similarly as in C prior to Western blotting and co-IP. F, KLF8 interaction with
PARP-1 is independent of PARP-1 catalytic activity or PIAS1 levels. PARP-1⫹/⫹
cells were transfected with HA-KLF8 for 24 h and treated with PJ-34 for
another 24 h prior to Western blotting and co-IP.

PARP-1⫹/⫹ MEFs with KLF8 and SUMO-1, treated the cells
with both doxorubicin and the PARP-1 inhibitor PJ-34, and
then examined the change in the SUMOylation state of KLF8.
The results showed that the levels of SUMOylated KLF8 were
markedly reduced when PARP-1 activity was inhibited (Fig. 4C,
compare lane 1 to lane 2), suggesting that the PARylation activity of PARP-1 is required for DNA damage-induced SUMOylation of KLF8. Time course observation revealed that the PIASassociated KLF8 and PARP-1 began to be released from PIASs
around 1 h post-doxorubicin removal (Fig. 4D), suggesting that
the KLF8-mediated DNA repair process may be finished quite
quickly.
To determine the role of the PARylation activity of PARP-1
in the interaction between PARP-1, PIAS1, and KLF8, we first
treated PIAS1-transfected PARP-1⫹/⫹ MEFs with both doxorubicin and PJ-34 and examined the interaction between
PARP-1 and PIAS1 by co-IP. We found that inhibition of
PARP-1 activity prevented DNA damage-enhanced interaction
between PARP-1 and PIAS1 (Fig. 4E), suggesting that the
PARylation activity of PARP-1 is critical for the interaction
between PARP-1 and PIAS1 during DNA damage. We found
that neither inhibition of PARP-1 activity nor overexpression of
PIAS1 affected the interaction between PARP-1 and KLF8 in
the cells (Fig. 4F), suggesting that KLF8 interaction with
PARP-1 is independent of PARP-1 catalytic activity or PIAS1
expression levels. Taken together, these results support the
notion that, during DNA damage, the catalytically active
PARP-1 recruits KLF8 and PIASs together to facilitate PIASs
catalyzed SUMOylation of KLF8 and subsequent DNA repair.
Phosphorylation of KLF8 at Ser-80 by DNA-PKcs Is Required
for the DNA Damage-induced SUMOylation of KLF8—The
kinase-specific phosphorylation sites on the KLF8 sequence
were analyzed using NetPhosK software online, resulting in an
interesting clue that the Ser-80 site of KLF8 is a potential phosphorylation target site for the serine kinase DNA-PKcs, another
master sensor of DNA damage and regulator of DNA repair
(32–34). To test whether Ser-80 plays a role in the DNA damage-induced SUMOylation of KLF8, the wild-type KLF8 or its
S80A mutant were compared for their SUMOylation states in
the PARP-1⫹/⫹ MEFs treated with doxorubicin. Unlike the
wild-type KLF8 that was well SUMOylated, the S80A mutant
showed no sign of being SUMOylated (Fig. 5A). This result
suggests that the potential phosphorylation of KLF8 at Ser-80
by a serine kinase plays a critical role in the DNA damageinduced SUMOylation of KLF8.
Co-IP experiments demonstrated an interaction between
KLF8 and DNA-PKcs that depends on the expression of
PARP-1 and KLF8 interaction with PARP-1 (Fig. 5B).
Silencing DNA-PKcs caused a significant decrease in the levels of DNA damage-induced SUMOylation of KLF8, and inhibiting DNA-PKcs catalytic activity with Nu7026 almost completely abolished the SUMOylation of KLF8 1 h after
doxorubicin removal (Fig. 5C, top panel, compare lanes 5 or 6 to
lane 1). This decrease in the SUMOylation of KLF8 was well
correlated with the reduction in the overall serine phosphorylation of KLF8 (Fig. 5C, center panel, compare lanes 5 or 6 to
lane 1). At the end of doxorubicin treatment, the levels of phosphorylation of KLF8 at serine residues were induced highly on
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the wild-type KLF8 and the K67R mutant but to a much less
extent on the S80A and ZF1,2mCs mutants (Fig. 5D). Taken
together, these results suggest that phosphorylation of KLF8 at
Ser-80, presumably by DNA-PKcs, could possibly play a priming role for the PARP-1-dependent SUMOylation of KLF8 by
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DISCUSSION
This study has identified a novel role and mechanisms for
KLF8 in promoting DNA repair in breast cancer cells. This
function of KLF8 depends on PARP-1 expression and activity,
DNA-PKcs-mediated phosphorylation of KLF8 at Ser-80, and
VOLUME 287 • NUMBER 52 • DECEMBER 21, 2012

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on March 21, 2019

FIGURE 5. The phosphorylation of KLF8 at Ser-80 by DNA-PKcs is required
for the SUMOylation of KLF8 upon DNA damage. A, the KLF8 S80A mutant
fails to be SUMOylated during DNA damage. PARP-1⫹/⫹ MEFs were transfected with HA-KLF8, HA-S80A, or vector alone along with Myc-SUMO-1. The
cells were treated with doxorubicin for 4 h followed by 2 h of recovery. Whole
cell lysates (WCL) were prepared for Western blotting (IB) and co-IP (IP). The
arrowhead, arrow, and asterisk indicate the SUMOylated KLF8, KLF8, and IgG
heavy chain, respectively. B, KLF8 interacts with DNA-PKcs in a PARP-1-dependent fashion. PARP-1⫹/⫹ cells and PARP-1⫺/⫺ cells were cotransfected with
HA-KLF8, HA-ZF1,2mCs, or HA-S80A, treated similarly as in A, and prepared for
Western blotting and co-IP. C, DNA-PKcs is required for the phosphorylation,
and SUMOylation of KLF8. PARP-1⫹/⫹ cells were transfected with indicated
HA-tagged WT KLF8 or its mutants along with siRNA against DNA-PKcs (siDPK)
for 48 h or with 2.5 M of the DNA-PKcs inhibitor Nu7026 (Nu) for 10 h. The
cells were then treated with doxorubicin for 4 h. Whole cell lysates were prepared for IP with HA antibodies followed by Western blotting with phosphoserine (pSer) antibodies or DNA-PKcs (DPK) antibodies. The arrowhead
indicates SUMOylated KLF8. D, the S80A and ZF1,2mCs mutants are less serine-phosphorylated than the wild-type KLF8 during DNA damage. PARP-1⫹/⫹
MEFs were transfected with indicated HA-tagged KLF8 WT or mutants for 48 h
and treated with doxorubicin or vehicle control for 4 h. Whole cell lysates
(WCL) were prepared for indicated Western blotting and co-IP (top panel). The
ratio of serine-phosphorylated KLF8 to total KLF8 was normalized to the
doxorubicin-treated wild-type KLF8-expressing group (bottom panel). Data
represent the mean ⫾ S.E. of at least three independent duplicate experiments. *, p ⬍ 0.05. E, KLF8 is serine-phosphorylated in response to DNA damage in MDA-MB-231 cells. The cells were treated with doxorubicin or vehicle
control for 4 h, followed by 2 h recovery. Whole cell lysates were prepared for
Western blotting and co-IP. IgG, IP negative control. The arrows indicate
SUMOylated KLF8.

PIASs during the cell response to doxorubicin-induced DNA
damage.
The Phosphorylation and SUMOylation of KLF8 and Its
Interaction with PARP-1, DNA-PKcs, and PIASs Are Critical for
Its Role in Promoting DNA Repair and Cell Survival in Breast
Cancer Cells—To test if the aforementioned multiple posttranslational modifications and protein-protein interactions
also take place in breast cancer cells encountering DNA damage, we first treated the MDA-MB-231 cells and examined the
serine-phosphorylation state of KLF8. We found that, as seen in
the PARP-1⫹/⫹ MEFs, the levels of the KLF8 phosphorylation
was markedly increased in response to doxorubicin treatment
(Fig. 5E).
We then determined whether PARP-1 activity and expression are important in the KLF8-promoted DNA repair and cell
survival against DNA damage. We grew the 231-K8ikd cells
under uninduced (U) or induced (I) conditions, treated the cells
simultaneously with both doxorubicin and the PARP-1 inhibitor or siRNAs, and examined the impact of the treatments on
the levels of DNA damage and cell viability. We found that the
doxorubicin-induced DNA damage was markedly enhanced
when KLF8 expression in the cancer cells was silenced (I) (Fig.
6A, compare I and U). When PARP-1 activity was inhibited in
the cells, the levels of DNA damage were increased similarly,
regardless of the expression (U ⫹ ABT) or knockdown (I ⫹
ABT) of KLF8 in the cells (Fig. 6A, compare the ABT-treated
and untreated groups). The increase in DNA damage levels was
inversely correlated with cell viability (Fig. 6B). Silencing
PARP-1 expression in the cells had an impact on cell viability
similar to that caused by KLF8 knockdown (Fig. 6C). In MCF10A cells, on the other hand, overexpression of the wild-type
KLF8 but not the ZF1,2mCs, S80A, or K67R mutant, could significantly increase the cell resistance to doxorubicin-induced
DNA damage (Fig. 6D) and cell death (E). These results strongly
suggest that the multiple forms of protein modifications and
interactions centering on KLF8 are critical for DNA repair and
therapeutic resistance to DNA damage-induced death of
human breast cancer cells.
The Phosphorylation and SUMOylation of KLF8 Redirects It
to the DNA Damage Site during DNA Repair—To determine
whether KLF8 is recruited to the DNA damage site during DNA
damage response, the transcriptional activity of KLF8 on the
promoter of cyclin D1, a known target of KLF8, and the presence of KLF8 at the DNA DSBs were examined. We found that
in response to DNA damage, the activity of KLF8 on the cyclin
D1 promoter was reduced in a Ser-80- and Lys-67-dependent
manner (Fig. 7A) and that KLF8 was recruited to the DNA DSBs
(B). These results suggest that the KLF8 protein was redirected
from a target gene locus not associated with DNA damage to
DNA damage site to facilitate DNA repair and that the phosphorylation and SUMOylation of KLF8 is critical for this redirection process.

KLF8 Regulates DNA Repair

FIGURE 6. Multiple posttranslational modifications are involved in KLF8mediated, PARP-1-dependent DNA repair and cell survival in breast cancer cells. A, PARP-1 catalytic activity is required for KLF8-promoted DNA
repair in breast cancer cells. 231-K8iKd cells were grown with or without 1
g/ml doxycycline to induce (I) or uninduce (U) the knockdown of KLF8. After
48 h, 2.5 M of the PARP-1 inhibitor ABT-888 (ABT) was added for 8 h. The cells
were then treated with 1 M doxorubicin (Doxo) for indicated periods of time
and processed for Western blotting (IB). B and C, PARP-1 catalytic activity is
required for KLF8-dependent cell survival. 231-K8iKd cells were grown as in A.
After 4 h of treatment with doxorubicin and 2 h of recovery, the cells were
processed for WST-1 assay (B), or 231-K8iKd cells were transfected with indicated siRNAs for 24 h under U conditions and then grown in U or I conditions
for 48 h. After 4 h of treatment with doxorubicin and 2 h of recovery, the cells
were processed for WST-1 assay (C). D and E, disruption of PARP-1 interaction,
phosphorylation on Ser-80 or SUMOylation on Lys-67 reduces the ability of
KLF8 to promote DNA repair and cell survival. MCF-10A cells were transfected
with HA-tagged wild-type KLF8 (WT), indicated mutants, or vector alone for
24 h and treated with doxorubicin for 4 h followed by 2 h of recovery. Cells
were then prepared for Western blotting (D) or clonogenic assay (E). *, p ⬍
0.05 compared with any one of the other three groups. Data represent the
mean ⫾ S.E. of three independent triplicate experiments.

PIAS-catalyzed SUMOylation of KLF8. These findings suggest
a potentially important mechanism underlying therapeutic
resistance of breast cancer cells. Inhibitors of both PARP-1 and
DNA-PKcs have been under active clinical trials for treatment
of cancers of particularly BRCA-deficient types (1). Protein
SUMOylation is generally accepted as a cellular process favoring tumor progression, and inhibitors of SUMOylation have
also been explored as anti-cancer drugs (6). This work sheds
new light on the drug-resistant mechanisms of breast cancer
and advances the knowledge for designing novel strategies for
breast cancer treatment.
Genotoxic anti-cancer drugs such as doxorubicin, proflavine, and daunomycin cause SSBs in treated cells. Failure to fix
the SSBs will subsequently result in DSBs. SSBs and DSBs are
primarily repaired by PARP-1 and BRCAs or DNA-PK, respecDECEMBER 21, 2012 • VOLUME 287 • NUMBER 52

tively (2, 4, 5). Our finding that KLF8 interacts with and is regulated by both PARP-1 and DNA-PKcs in the cells exposed to
doxorubicin suggests that KLF8 may participate in both SSB
and DSB repair processes.
Many interesting questions emerge regarding exactly what
role KLF8 plays in protecting DNA. We have shown recently
shown that KLF8 actively regulates the expression of genes that
are associated with cell cycle progression and epithelial-tomesenchymal transition such as cyclin D1, E-cadherin, and
MMP9 in actively proliferating cells, including breast cancer
cells (10, 11, 23, 26). We have also demonstrated that PARP-1
binding and modification of KLF8 are critical for KLF8 regulation of these genes and cellular processes (20) and that SUMOylation of KLF8 delimits such roles of KLF8 (18). In addition,
one of the primary changes in SUMOylated proteins is their
subcellular relocation to interact with distinct binding partner
molecules (6, 7). Therefore, it appears likely that the cellular
response to the DNA damage signals KLF8 away from these
proliferation-promoting genes. PARP-1 appears to work as a
“switchman” using SUMOylation of KLF8 as the “switch” to
control the process. In other words, there appears to be a PARP1-associated pool of KLF8 proteins. Depending upon the cell
need, the KLF8 proteins are dispatched from this pool to distinct functional sites of KLF8. We speculate that in response to
the DNA damage call, PARP-1 first aids in the SUMOylation of
KLF8 and then redispatches it away from loci of proliferationpromoting genes. From there, PARP-1 further takes the
SUMOylated KLF8 to the DNA damage sites and they work
there together to fix the damage, or it sends KLF8 to loci of a
different group of KLF8 target genes or microRNAs responsible
for cell cycle arrest, DNA repair or protection, or anti-apoptosis
(Fig. 8). Experiments are in progress to uncover the details of
these very interesting possibilities. It is less plausible that all
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. The phosphorylation at Ser-80 and the SUMOylation at Lys-67
of KLF8 are responsible for its reduced activity on the cyclin D1 promoter
and its recruitment to the DNA damage site during DNA repair. A, the
S80A and K67R mutants failed to respond to DNA damage in activating the
cyclin D1 promoter. NIH3T3 cells were transfected with the cyclin D1 promoter reporter plasmid along with the indicated KLF8 DNAs or vector alone
for 30 h. DNA damage was induced by 1 M doxorubicin (Doxo) for 4 h of
treatment, followed by 1 h of recovery. Dural luciferase assays were performed as described under “Experimental Procedures.” The data in the graph
represent the mean ⫾ S.E. of at least three independent duplicate experiments. *, p ⬍ 0.05. B, recruitment of KLF8 to double-stranded DNA breaks. The
DNA damage site-targeted ChIP was performed as described under “Experimental Procedures.”
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that happens to KLF8 during DNA damage response is to help
brake the cell cycle wheel only.
Whatever the molecular action of KLF8 is on the DNA damage response, its prior SUMOylation, which is achieved by a
combined effect from PARP-1, DNA-PKcs, and PIASs, seems
to be essential. It has been suggested that phosphorylation plays
an important role in initiating or promoting the SUMOylation
of the same protein molecule (6). Although the amino acid
sequence spanning the Lys-67 SUMOylation site and the
Ser-80 site of KLF8 does not exactly match the predicted
consensus sequence of the so-called phosphorylation-dependent SUMOylation motif (35, 36), the negative charges brought
to the proximity to the Lys-67 by DNA-PKcs-catalyzed phosphorylation of the Ser-80 site could turn the region into a motif
very similar to another SUMOylation consensus motif named
negatively charged amino acid-dependent SUMOylation motif
(37). It will be interesting to test whether it is essential for the
phosphorylation of KLF8 at the Ser-80 by DNA-PKcs to prime
the SUMOylation of KLF8 at Lys-67.
We have demonstrated recently that KLF8 interaction with
PARP-1 in the nucleus does not depend upon PARP-1 activity,
whereas KLF8 transactivation of its target gene promoters, such
as cyclin D1, requires the PARylation of PARP-1 itself and of
KLF8 (20). Our results here indicate that both the interaction of
PARP-1 with KLF8, DNA-PKcs, and PIASs and the PARylation
activity of PARP-1 are required for the SUMOylation of KLF8
during DNA damage. To the best of our knowledge, there has
not been any report on PARylation of DNA-PKCS or PAISs.
Further studies are worth doing to determine whether or not
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FIGURE 8. A model of redirection of KLF8 to DNA damage site during DNA
repair. In the absence of DNA damage, KLF8 primarily targets target gene
locus A (TGL A) not related to DNA repair, such as the cyclin D1 gene. In
response to DNA damage, KLF8 is redirected to the DNA damage sites where
it contributes to DNA repair in an unknown way. KLF8 could be redirected to
a different TGL such as TGL B outside of the DNA damage site to regulate
expression of genes associated with DNA repair. PARP-1-dependent phosphorylation and SUMOylation of KLF8 is critical for the redirection of KLF8.

PARP-1 needs to catalyze the PARylation of any of the three
interacting proteins to ensure the SUMOylation of KLF8.
DNA damage-based chemotherapies depend on the failure
of cancer cells to repair the DNA damage and subsequent cell
death. Aberrant high levels of DNA repair function in the cells
likely increase not only the resistance of the cells to such therapies but also the malignancy of the cells because of improper
DNA repair-mediated genomic and chromosomal instability.
Indeed, our results have clearly linked the KLF8-promoted
DNA repair to the cell resistance to doxorubicin-induced cell
death. It remains to be determined whether KLF8 plays a similar role in repairing DNA damage caused by other types of
genotoxic agents, such as DNA alkylating agents and ionizing
radiation. Nevertheless, our results suggest that, in addition to
enhancing the drug resistance of the cancer cells, KLF8 could
play a role in disturbing genomic integrity through its aberrant
DNA repair function to subsequently contribute to aggressive
progression of cancer.
In summary, this work has identified KLF8 as a novel regulator of DNA repair in human breast cancer cells. Given its barely
detectable expression in normal human breast epithelial cells
and tissue (10, 11), KLF8 may represent a novel target for DNA
repair-targeted therapy against breast cancer drug resistance.

KLF8 Regulates DNA Repair

15.

16.

17.

18.

19.

21.

22.

23.

24.

25.

26.

DECEMBER 21, 2012 • VOLUME 287 • NUMBER 52

27.

28.

29.

30.
31.
32.

33.

34.

35.
36.

37.

Feustel, P. J., and Zhao, J. (2011) KLF8 promotes human breast cancer cell
invasion and metastasis by transcriptional activation of MMP9. Oncogene
30, 1901–1911
Zhao, J., Pestell, R., and Guan, J. L. (2001) Transcriptional activation of
cyclin D1 promoter by FAK contributes to cell cycle progression. Mol.
Biol. Cell 12, 4066 – 4077
Pierce, A. J., Johnson, R. D., Thompson, L. H., and Jasin, M. (1999) XRCC3
promotes homology-directed repair of DNA damage in mammalian cells.
Genes Dev. 13, 2633–2638
Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F.,
Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., Kunkel, T. A., van
Harn, T., Xia, B., Correll, M., Quackenbush, J., Livingston, D. M., Gygi,
S. P., and Sicinski, P. (2011) A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474,
230 –234
Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J., and van Bree, C.
(2006) Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315–2319
Zhao, J., and Guan, J. L. (2009) Signal transduction by focal adhesion
kinase in cancer. Cancer Metastasis Rev. 28, 35– 49
Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel,
S., Wang, X., Liang, H., Yu, J., Palanisamy, N., Siddiqui, J., Yan, W., Cao, X.,
Mehra, R., Sabolch, A., Basrur, V., Lonigro, R. J., Yang, J., Tomlins, S. A.,
Maher, C. A., Elenitoba-Johnson, K. S., Hussain, M., Navone, N. M., Pienta, K. J., Varambally, S., Feng, F. Y., and Chinnaiyan, A. M. (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS
gene fusion-positive prostate cancer. Cancer Cell 19, 664 – 678
Sajish, M., Zhou, Q., Kishi, S., Valdez, D. M., Jr., Kapoor, M., Guo, M., Lee,
S., Kim, S., Yang, X. L., and Schimmel, P. (2012) Trp-tRNA synthetase
bridges DNA-PKcs to PARP-1 to link IFN-␥ and p53 signaling. Nat. Chem.
Biol. 15, 547–554
Yoon, J. H., Ahn, S. G., Lee, B. H., Jung, S. H., and Oh, S. H. (2012) Role of
autophagy in chemoresistance. Regulation of the ATM-mediated DNAdamage signaling pathway through activation of DNA-PKcs and PARP-1.
Biochem. Pharmacol. 83, 747–757
Yang, X. J., and Grégoire, S. (2006) A recurrent phospho-sumoyl switch in
transcriptional repression and beyond. Mol. Cell 23, 779 –786
Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M., Palvimo, J. J.,
Nakai, A., and Sistonen, L. (2006) PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. U.S.A. 103, 45–50
Yang, S. H., Galanis, A., Witty, J., and Sharrocks, A. D. (2006) An extended
consensus motif enhances the specificity of substrate modification by
SUMO. EMBO J. 25, 5083–5093

JOURNAL OF BIOLOGICAL CHEMISTRY

43729

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on March 21, 2019

20.

(2012) Lentivirus-delivered Krüppel-like factor 8 small interfering RNA
inhibits gastric cancer cell growth in vitro and in vivo. Tumour Biol 33,
53– 61
Cox, B. D., Natarajan, M., Stettner, M. R., and Gladson, C. L. (2006) New
concepts regarding focal adhesion kinase promotion of cell migration and
proliferation. J. Cell. Biochem. 99, 35–52
Schnell, O., Romagna, A., Jaehnert, I., Albrecht, V., Eigenbrod, S., Juerchott, K., Kretzschmar, H., Tonn, J. C., and Schichor, C. (2012) Krüppellike factor 8 (KLF8) is expressed in gliomas of different WHO grades and
is essential for tumor cell proliferation. PLoS ONE 7, e30429
Wan, W., Zhu, J., Sun, X., and Tang, W. (2012) Small interfering RNA
targeting Krüppel-like factor 8 inhibits U251 glioblastoma cell growth by
inducing apoptosis. Mol. Med. Report 5, 347–350
Wei, H., Wang, X., Gan, B., Urvalek, A. M., Melkoumian, Z. K., Guan, J. L.,
and Zhao, J. (2006) Sumoylation delimits KLF8 transcriptional activity
associated with the cell cycle regulation. J. Biol. Chem. 281, 16664 –16671
Urvalek, A. M., Lu, H., Wang, X., Li, T., Yu, L., Zhu, J., Lin, Q., and Zhao,
J. (2011) Regulation of the oncoprotein KLF8 by a switch between acetylation and sumoylation. Am. J. Transl. Res. 3, 121–132
Lu, H., Wang, X., Li, T., Urvalek, A. M., Yu, L., Li, J., Zhu, J., Lin, Q., Peng,
X., and Zhao, J. (2011) Identification of poly (ADP-ribose) polymerase-1
(PARP-1) as a novel Krüppel-like factor 8-interacting and -regulating protein. J. Biol. Chem. 286, 20335–20344
Mehta, T. S., Lu, H., Wang, X., Urvalek, A. M., Nguyen, K. H., Monzur, F.,
Hammond, J. D., Ma, J. Q., and Zhao, J. (2009) A unique sequence in the
N-terminal regulatory region controls the nuclear localization of KLF8 by
cooperating with the C-terminal zinc-fingers. Cell Res. 19, 1098 –1109
Urvalek, A. M., Wang, X., Lu, H., and Zhao, J. (2010) KLF8 recruits the
p300 and PCAF co-activators to its amino terminal activation domain to
activate transcription. Cell Cycle 9, 601– 611
Zhao, J., Bian, Z. C., Yee, K., Chen, B. P., Chien, S., and Guan, J. L. (2003)
Identification of transcription factor KLF8 as a downstream target of focal
adhesion kinase in its regulation of cyclin D1 and cell cycle progression.
Mol. Cell. 11, 1503–1515
Zerfaoui, M., Errami, Y., Naura, A. S., Suzuki, Y., Kim, H., Ju, J., Liu, T.,
Hans, C. P., Kim, J. G., Abd Elmageed, Z. Y., Koochekpour, S., Catling, A.,
and Boulares, A. H. (2010) Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-B
upon TLR4 stimulation. J. Immunol. 185, 1894 –1902
Wang, Z. Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., Schulze-Osthoff, K., and Wagner, E. F. (1997) PARP is important for genomic stability
but dispensable in apoptosis. Genes Dev. 11, 2347–2358
Wang, X., Lu, H., Urvalek, A. M., Li, T., Yu, L., Lamar, J., DiPersio, C. M.,

A Novel Role of Krüppel-like Factor 8 in DNA Repair in Breast Cancer Cells
Heng Lu, Liu Hu, Tianshu Li, Satadru Lahiri, Chao Shen, Melissa S. Wason, Debarati
Mukherjee, Hui Xie, Lin Yu and Jihe Zhao
J. Biol. Chem. 2012, 287:43720-43729.
doi: 10.1074/jbc.M112.418053 originally published online October 26, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.418053

Click here to choose from all of JBC's e-mail alerts
This article cites 37 references, 9 of which can be accessed free at
http://www.jbc.org/content/287/52/43720.full.html#ref-list-1

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on March 21, 2019

Alerts:
• When this article is cited
• When a correction for this article is posted

